These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 27440710

  • 1. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W, Sun J, Zhou L, Li Y, Wu X.
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [Abstract] [Full Text] [Related]

  • 2. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 3. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 4. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR.
    Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
    [Abstract] [Full Text] [Related]

  • 5. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Grey A, Bolland M, Mihov B, Wong S, Horne A, Gamble G, Reid IR.
    J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
    Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D.
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4481-90. PubMed ID: 23024190
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
    Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.
    Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A, FOCUS-D Investigators.
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [Abstract] [Full Text] [Related]

  • 11. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON.
    Popp AW, Buffat H, Cavelti A, Windolf M, Perrelet R, Senn C, Lippuner K.
    Maturitas; 2014 Mar; 77(3):287-93. PubMed ID: 24485216
    [Abstract] [Full Text] [Related]

  • 12. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H.
    J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
    Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R.
    J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
    [Abstract] [Full Text] [Related]

  • 18. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG.
    N Engl J Med; 2014 Jan 30; 370(5):412-20. PubMed ID: 24382002
    [Abstract] [Full Text] [Related]

  • 19. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P, Kauka A, Ziller M, Birkholz K, Baier M, Muth M, Bauer M.
    Osteoporos Int; 2014 Apr 30; 25(4):1369-78. PubMed ID: 24504100
    [Abstract] [Full Text] [Related]

  • 20. Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China.
    Zhang Y, Wang Y.
    J Nutr Health Aging; 2020 Apr 30; 24(5):485-493. PubMed ID: 32346686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.